iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $101.38, for a total value of $506,900.00. Following the completion of the transaction, the chief executive officer owned 2,242,500 shares of the company’s stock, valued at approximately $227,344,650. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

iRadimed Stock Down 3.0%

iRadimed stock opened at $99.67 on Thursday. The stock has a 50-day moving average price of $100.46 and a 200 day moving average price of $89.23. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 56.95 and a beta of 1.12. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were paid a $0.20 dividend. The ex-dividend date was Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is currently 45.71%.

Hedge Funds Weigh In On iRadimed

Several institutional investors have recently made changes to their positions in IRMD. Hsbc Holdings PLC boosted its position in iRadimed by 19.2% during the fourth quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock worth $2,103,000 after purchasing an additional 3,468 shares in the last quarter. Aristides Capital LLC grew its holdings in iRadimed by 5.0% in the fourth quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock valued at $2,698,000 after purchasing an additional 1,309 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after buying an additional 205,783 shares in the last quarter. Invesco Ltd. raised its stake in shares of iRadimed by 473.9% during the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after buying an additional 29,010 shares during the period. Finally, NewEdge Advisors LLC acquired a new position in shares of iRadimed during the 4th quarter worth approximately $1,679,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IRMD has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Lake Street Capital reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.